ClinicalTrials.gg
CompletedNCT00346216PRECISIONUpdated Mar 3, 2021Results posted

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

A Phase 4 interventional study of celecoxib and Ibuprofen in Arthritis, Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1,066 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24,081
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
2nd of 771
24,081 · median 120
Started
2006
with 34 others
Phase 4
61 of 975
none open now
Registered
121st of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 2nd largest by enrollment of the 771 interventional ones that give a count, is one of 35 that started in 2006, is one of 61 in phase 4, and was the 121st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with osteoarthritis or rheumatoid Arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms.

Exclusion criteria

Exclusion Criteria:

  • Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;
  • Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial
  • Subjects require treatment with aspirin > 325 mg /day
  • Subjects with known to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24,081 participants (actual)

Study arms

  • Experimental
    celecoxib

    subject receives celecoxib and dummy (placebo) ibuprofen and naproxen

    Drug: celecoxib

  • Active comparator
    ibuprofen

    subject receives ibuprofen and dummy (placebo) celecoxib and naproxen

    Drug: Ibuprofen

  • Active comparator
    naproxen

    subject receives naproxen and dummy (placebo) celecoxib and ibuprofen

    Drug: Naproxen

Interventions

  • 100 to 200 mg twice daily, taken by mouth

  • ibuprofen 600 mg to 800 mg three times daily, taken by mouth

  • naproxen 375mg to 500 mg twice daily, taken by mouth

06

What researchers measure

Primary outcomes

  1. The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

    APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology).

    Time frame: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months

Secondary outcomes

  1. The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

    MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA

    Time frame: ITT Population - 30 months; MITT Population - 42 months

  2. The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

    CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer

    Time frame: ITT Population - 30 months; MITT Population - 42 months

  3. Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

    VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain".

    Time frame: ITT and MITT Population - Baseline to 42 months

07

Results

Posted May 1, 2017

Participant flow

The study was conducted at 950 centers in Australia (11), Brazil (30), Canada (64), Colombia (7), Costa Rica (12), Hong Kong (4), Mexico (11), Panama (2), Peru (5), Philippines (8), Taiwan (10), Ukraine 19), and United States (767); a total of 24 sites were activated but did not randomized any subject.

Participant flow — Overall Study
MilestoneCelecoxibIbuprofenNaproxen
Started807280407969
Completed566455805621
Not completed240824602348
Withdrew: Other181231205
Withdrew: No longer willing to participate600606585
Withdrew: Withdrawal by subject661692651
Withdrew: Lost to follow-up611588542
Withdrew: Physician decision807659
Withdrew: Does not meet entrance criteria13108
Withdrew: Death189192228
Withdrew: Study terminated by sponsor1148
Withdrew: Missing subject summary status626162

Outcome measures

PrimaryThe First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology).

Time frame:
Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
Reported as:
Number · Percentage of Partcipants
The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).
Percentage of PartcipantsCelecoxibIbuprofenNaproxen
ITT (N = 8072, 8040, 7969)2.32.72.5
MITT (N = 8030, 7990, 7933)1.71.91.8
Statistical analysis
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.0002 (Non inferiority P value, α=0.025) · Hazard ratio (hr): 0.93 · 95% CI 0.76 to 1.13
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.0001 (Non inferiority P value, α=0.025) · Hazard ratio (hr): 0.90 · 95% CI 0.72 to 1.14
  • Celecoxib vs Ibuprofen · Regression, Cox · p = <0.0001 (Non inferiority P value, α=0.025) · Hazard ratio (hr): 0.86 · 95% CI 0.70 to 1.04
  • Celecoxib vs Ibuprofen · Regression, Cox · p = <0.0001 (Non-inferiority P-value, α=0.025) · Hazard ratio (hr): 0.81 · 95% CI 0.64 to 1.02
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.0182 (Non-inferiority P-value, α=0.025) · Hazard ratio (hr): 1.08 · 95% CI 0.89 to 1.31
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.0250 (Non-inferiority P-value, α=0.025) · Hazard ratio (hr): 1.12 · 95% CI 0.89 to 1.40
SecondaryThe First Occurrence of a Major Adverse Cardiovascular Events (MACE)

MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA

Time frame:
ITT Population - 30 months; MITT Population - 42 months
Reported as:
Number · Percentage of Participants
The First Occurrence of a Major Adverse Cardiovascular Events (MACE)
Percentage of ParticipantsCelecoxibIbuprofenNaproxen
ITT (N = 8072, 8040, 7969)4.24.84.3
MITT (N = 8030, 7990, 7933)3.13.63.2
Statistical analysis
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.6427 · Hazard ratio (hr): 0.97 · 95% CI 0.83 to 1.12
  • Celecoxib vs Ibuprofen · Regression, Cox · p = 0.0597 · Hazard ratio (hr): 0.87 · 95% CI 0.75 to 1.01
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.1481 · Hazard ratio (hr): 1.11 · 95% CI 0.96 to 1.29
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.5758 · Hazard ratio (hr): 0.95 · 95% CI 0.80 to 1.13
  • Celecoxib vs Ibuprofen · Regression, Cox · p = 0.0204 · Hazard ratio (hr): 0.82 · 95% CI 0.69 to 0.97
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.0751 · Hazard ratio (hr): 1.17 · 95% CI 0.98 to 1.38
SecondaryThe First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer

Time frame:
ITT Population - 30 months; MITT Population - 42 months
Reported as:
Number · Percentage of Participants
The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)
Percentage of ParticipantsCelecoxibIbuprofenNaproxen
ITT (N = 8072, 8040, 7969)0.70.90.7
MITT (N = 8030, 7990, 7933)0.30.70.7
Statistical analysis
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.8576 · Hazard ratio (hr): 0.97 · 95% CI 0.67 to 1.40
  • Celecoxib vs Ibuprofen · Regression, Cox · p = 0.1202 · Hazard ratio (hr): 0.76 · 95% CI 0.53 to 1.08
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.1734 · Hazard ratio (hr): 1.27 · 95% CI 0.90 to 1.81
  • Celecoxib vs Naproxen · Regression, Cox · p = 0.0041 · Hazard ratio (hr): 0.51 · 95% CI 0.32 to 0.81
  • Celecoxib vs Ibuprofen · Regression, Cox · p = 0.0003 · Hazard ratio (hr): 0.43 · 95% CI 0.27 to 0.68
  • Ibuprofen vs Naproxen · Regression, Cox · p = 0.4243 · Hazard ratio (hr): 1.16 · 95% CI 0.80 to 1.69
SecondaryChange From Baseline in Patient's Assessment of Arthritis Pain (VAS)

VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain".

Time frame:
ITT and MITT Population - Baseline to 42 months
Reported as:
Mean · Number of participants
Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)
Number of participantsCelecoxibIbuprofenNaproxen
Baseline (ITT) N= 8014, 8001, 792854.0 ± 23.5354.1 ± 23.5854.1 ± 24.04
Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325-8.2 ± 24.69-9.0 ± 25.69-9.9 ± 25.53
Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149-10.5 ± 26.39-10.6 ± 26.92-11.1 ± 26.83
Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740-11.4 ± 27.70-11.7 ± 28.10-12.3 ± 27.80
Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159-11.7 ± 28.92-12.1 ± 28.97-12.1 ± 28.83
Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846-11.0 ± 29.15-11.6 ± 29.29-11.9 ± 29.30
Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246-11.3 ± 29.11-11.3 ± 29.10-11.7 ± 29.33
Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785-11.3 ± 29.44-11.5 ± 28.98-11.4 ± 29.27
Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086-10.5 ± 29.81-11.2 ± 29.71-11.3 ± 29.71
Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635-10.1 ± 29.61-10.7 ± 29.62-11.6 ± 29.80
Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439-11.4 ± 29.78-11.1 ± 30.14-12.1 ± 30.27
Baseline (MITT) N=7974, 7954, 789454.0 ± 23.5354.1 ± 23.5854.1 ± 24.02
Change-Baseline to Mon1 MITT N=7372, 7367, 7321-8.2 ± 24.69-9.0 ± 25.67-9.9 ± 25.53
Change-Baseline to Mon2 MITT N=7170, 7078, 7142-10.5 ± 26.38-10.6 ± 26.92-11.1 ± 26.84
Change-Baseline to Mon4 MITT N=6772, 6686, 6732-11.4 ± 27.70-11.7 ± 28.10-12.3 ± 27.81
Change-Baseline to Mon8 MITT N=6224, 6128, 6155-11.7 ± 28.93-12.1 ± 28.97-12.1 ± 28.84
Change-Baseline to Mon12 MITT N=5787, 5689, 5844-11.0 ± 29.16-11.6 ± 29.30-11.9 ± 29.30
Change-Baseline to Mon18 MITT N=5305, 5175, 5242-11.3 ± 29.11-11.3 ± 29.12-11.7 ± 29.33
Change-Baseline to Mon24 MITT N=4815, 4769, 4782-11.4 ± 29.44-11.5 ± 29.00-11.3 ± 29.26
Change-Baseline to Mon30 MITT N=4139, 4067, 4085-10.5 ± 29.81-11.2 ± 29.71-11.3 ± 29.70
Change-Baseline to Mon36 MITT N=3691, 3623, 3635-10.2 ± 29.61-10.7 ± 29.62-11.6 ± 29.80
Change-Baseline to Mon42 MITT N=3468, 3404, 3438-11.4 ± 29.78-11.1 ± 30.14-12.1 ± 30.27
Statistical analysis
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 1.77 · 95% CI 1.01 to 2.53
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.0373 · Mean difference (final values): 0.81 · 95% CI 0.05 to 1.56
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0129 · Mean difference (final values): 0.96 · 95% CI 0.20 to 1.72
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.1830 · Mean difference (final values): 0.52 · 95% CI -0.25 to 1.29
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.7777 · Mean difference (final values): -0.11 · 95% CI -0.88 to 0.66
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.1072 · Mean difference (final values): 0.63 · 95% CI -0.14 to 1.40
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.8237 · Mean difference (final values): 0.67 · 95% CI -0.12 to 1.46
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.8237 · Mean difference (final values): -0.09 · 95% CI -0.88 to 0.70
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0587 · Mean difference (final values): 0.76 · 95% CI -0.03 to 1.55
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.3129 · Mean difference (final values): 0.42 · 95% CI -0.39 to 1.23
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.6526 · Mean difference (final values): 0.19 · 95% CI -0.63 to 1.00
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.5774 · Mean difference (final values): 0.23 · 95% CI -0.58 to 1.05
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.0632 · Mean difference (final values): 0.79 · 95% CI -0.04 to 1.62
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.4540 · Mean difference (final values): 0.32 · 95% CI -0.52 to 1.15
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.2705 · Mean difference (final values): 0.47 · 95% CI -0.37 to 1.30
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.5225 · Mean difference (final values): 0.28 · 95% CI -0.58 to 1.14
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.5996 · Mean difference (final values): -0.23 · 95% CI -1.10 to 0.63
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.2461 · Mean difference (final values): 0.51 · 95% CI -0.35 to 1.38
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.8127 · Mean difference (final values): 0.11 · 95% CI -0.79 to 1.00
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.9641 · Mean difference (final values): -0.02 · 95% CI -0.92 to 0.87
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.7784 · Mean difference (final values): 0.13 · 95% CI -0.77 to 1.03
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.2105 · Mean difference (final values): 0.61 · 95% CI -0.34 to 1.56
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.2909 · Mean difference (final values): 0.51 · 95% CI -0.44 to 1.46
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.8459 · Mean difference (final values): 0.09 · 95% CI -0.86 to 1.05
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.1116 · Mean difference (final values): 0.81 · 95% CI -0.19 to 1.80
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.9751 · Mean difference (final values): 0.02 · 95% CI -0.98 to 1.01
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.1202 · Mean difference (final values): 0.79 · 95% CI -0.21 to 1.79
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.3767 · Mean difference (final values): 0.46 · 95% CI -0.56 to 1.48
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.1123 · Mean difference (final values): -0.83 · 95% CI -1.85 to 0.19
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0137 · Mean difference (final values): 1.29 · 95% CI 0.26 to 2.31
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 1.77 · 95% CI 1.07 to 2.47
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.0197 · Mean difference (final values): 0.84 · 95% CI 0.13 to 1.54
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0094 · Mean difference (final values): 0.93 · 95% CI 0.23 to 1.64
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.1247 · Mean difference (final values): 0.57 · 95% CI -0.16 to 1.31
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.8278 · Mean difference (final values): -0.08 · 95% CI -0.81 to 0.65
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0802 · Mean difference (final values): 0.65 · 95% CI -0.08 to 1.39
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.0822 · Mean difference (final values): 0.68 · 95% CI -0.09 to 1.46
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.8314 · Mean difference (final values): -0.08 · 95% CI -0.86 to 0.69
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0516 · Mean difference (final values): 0.77 · 95% CI -0.01 to 1.54
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.3202 · Mean difference (final values): 0.42 · 95% CI -0.40 to 1.24
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.5893 · Mean difference (final values): 0.23 · 95% CI -0.60 to 1.05
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.6510 · Mean difference (final values): 0.19 · 95% CI -0.63 to 1.01
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.0796 · Mean difference (final values): 0.76 · 95% CI -0.09 to 1.62
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.5061 · Mean difference (final values): 0.29 · 95% CI -0.57 to 1.15
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.2796 · Mean difference (final values): 0.47 · 95% CI -0.38 to 1.33
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.6725 · Mean difference (final values): 0.19 · 95% CI -0.69 to 1.08
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.6381 · Mean difference (final values): -0.21 · 95% CI -1.10 to 0.67
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.3737 · Mean difference (final values): 0.40 · 95% CI -0.49 to 1.29
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.9139 · Mean difference (final values): 0.05 · 95% CI -0.87 to 0.97
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.9998 · Mean difference (final values): 0.00 · 95% CI -0.92 to 0.92
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.9144 · Mean difference (final values): 0.05 · 95% CI -0.88 to 0.98
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.2250 · Mean difference (final values): 0.62 · 95% CI -0.38 to 1.61
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.2758 · Mean difference (final values): 0.55 · 95% CI -0.44 to 1.55
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.9030 · Mean difference (final values): 0.06 · 95% CI -0.94 to 1.06
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.0910 · Mean difference (final values): 0.90 · 95% CI -0.14 to 1.94
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.7668 · Mean difference (final values): 0.16 · 95% CI -0.88 to 1.20
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.1653 · Mean difference (final values): 0.74 · 95% CI -0.31 to 1.78
  • Celecoxib vs Naproxen · Mixed Models Analysis · p = 0.4323 · Mean difference (final values): 0.43 · 95% CI -0.65 to 1.52
  • Celecoxib vs Ibuprofen · Mixed Models Analysis · p = 0.1439 · Mean difference (final values): -0.81 · 95% CI -1.89 to 0.28
  • Ibuprofen vs Naproxen · Mixed Models Analysis · p = 0.0251 · Mean difference (final values): 1.24 · 95% CI 0.16 to 2.33

Adverse events

Collected over Adverse events were reported from the signing of the informed consent throughout the entire study period (42 months) and including 30 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—1,473/8,030 (18.3%)4,268/8,030 (53.2%)
Ibuprofen—1,624/7,992 (20.3%)4,363/7,992 (54.6%)
Naproxen—1,611/7,933 (20.3%)4,337/7,933 (54.7%)
Most frequent serious events
Showing 10 of 1,222
Most frequent serious events
EventCelecoxibIbuprofenNaproxen
OsteoarthritisMusculoskeletal and connective tissue disorders201/8030206/7992189/7933
Chest painGeneral disorders52/803084/799273/7933
PneumoniaInfections and infestations64/803079/799269/7933
Myocardial infarctionCardiac disorders45/803070/799248/7933
Angina unstableCardiac disorders45/803041/799260/7933
Coronary artery diseaseCardiac disorders42/803040/799244/7933
ArthralgiaMusculoskeletal and connective tissue disorders44/803033/799239/7933
Cardiac failure congestiveCardiac disorders31/803041/799241/7933
Atrial fibrillationCardiac disorders35/803039/799236/7933
Acute kidney injuryRenal and urinary disorders36/803039/799231/7933
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCelecoxibIbuprofenNaproxen
HypertensionVascular disorders762/80301008/7992855/7933
OsteoarthritisMusculoskeletal and connective tissue disorders958/8030859/7992880/7933
ArthralgiaMusculoskeletal and connective tissue disorders764/8030659/7992764/7933
DiarrhoeaGastrointestinal disorders641/8030538/7992566/7933
Upper respiratory tract infectionInfections and infestations584/8030595/7992560/7933
Back painMusculoskeletal and connective tissue disorders542/8030516/7992547/7933
NauseaGastrointestinal disorders425/8030482/7992502/7933
BronchitisInfections and infestations465/8030471/7992427/7933
Pain in extremityMusculoskeletal and connective tissue disorders455/8030422/7992422/7933
Urinary tract infectionInfections and infestations416/8030452/7992414/7933

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CelecoxibIbuprofenNaproxenTotal
Mean63.0 ± 9.563.2 ± 9.463.3 ± 9.463.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibIbuprofenNaproxenTotal
Female51755174509615445
Male2897286628738636
08

Study locations

1,066 sites
  • Carol M. Johnson MD, LLC
    Alabaster, Alabama 35007, United States
  • Orthopaedics West
    Bessemer, Alabama 35022, United States
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Simon Williamson Clinic/Clinical Research Advantage, Inc.
    Birmingham, Alabama 35211, United States
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Cahaba Research Inc.
    Birmingham, Alabama 35242, United States
  • Winston Technology Inc.
    Haleyville, Alabama 35565, United States
  • Clinical Research Consultants, Inc
    Hoover, Alabama 35216, United States
  • Medical Affiliated Research Center, Incorporated
    Huntsville, Alabama 35801, United States
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Montgomery Rheumatology Associates
    Montgomery, Alabama 36111, United States
  • James P. Beretta, PC
    Pelham, Alabama 35124, United States
  • Alabama Clinical Research Associates
    Pell City, Alabama 35128, United States
  • Pell City Internal and Family Medicine
    Pell City, Alabama 35215, United States
  • Scottsboro Quick Care Clinic
    Scottsboro, Alabama 35768, United States
  • Clinic for Rheumatic Diseases
    Tuscaloosa, Alabama 35406, United States
  • Terence T. Hart , MD
    Tuscumbia, Alabama 35674, United States
  • Clinical Research Advantage Inc./ Warner Family Practice, PC
    Chandler, Arizona 85224, United States
  • ArthroCare, Arthritis Care & Research P.C.
    Gilbert, Arizona 85234, United States
  • Clinical Research Advantage Inc., /Thunderbird Internal Medicine
    Glendale, Arizona 85306-4652, United States
  • Arizona Center for Clinical Research
    Glendale, Arizona 85306, United States
  • Clinical Research Advantage, Inc./ Lenzmeier Family Medicine
    Glendale, Arizona 85308, United States
  • Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC
    Mesa, Arizona 85206, United States
  • Novara Clinical Research
    Mesa, Arizona 85206, United States
  • Clinical Research Advantage, Inc.
    Mesa, Arizona 85213, United States
  • Sun Valley Arthritis Center, Limited
    Peoria, Arizona 85381, United States
  • Lovelace Scientific Resources, Inc.
    Phoenix, Arizona 85016, United States
  • Clinical Research Advantage, Inc./ Family Practice Specialists, LTD
    Phoenix, Arizona 85018, United States
  • NPHC Research
    Phoenix, Arizona 85020, United States
  • Phoenix Clinical
    Phoenix, Arizona 85021, United States
  • Arizona Research Center, Inc.
    Phoenix, Arizona 85023, United States
  • Precision Trials AZ. LLC; AZ
    Phoenix, Arizona 85032, United States
  • 43rd Medical Associates, P.C.
    Phoenix, Arizona 85051, United States
  • Southwest Health Ltd.
    Scottsdale, Arizona 85254, United States
  • Advanced Arthritis Care and Research
    Scottsdale, Arizona 85258, United States
  • Arizona Pain Specialist, PLLC
    Scottsdale, Arizona 85258, United States
  • Sonora Quest Laboratories
    Scottsdale, Arizona 85258, United States
  • Cochise Clinical Research
    Sierra Vista, Arizona 85635, United States
  • Clinical Research Advantage, Inc./Skyline Medical Center PC
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Inc./Urban Family Practice Associates, PC
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Inc./Warner Family Practice, PC
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Inc/Manning Family Care
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Incl Colorado Springs Health Partners, East
    Tempe, Arizona 85282, United States
  • Family Medicine Associates/Clinical Research Advantage
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC
    Tempe, Arizona 85283, United States
  • ARA-Arizona Research Associates
    Tucson, Arizona 85712, United States
  • Canyon Clinical Research LLC
    Tucson, Arizona 85712, United States
  • Tucson Clinical Researh
    Tucson, Arizona 85712, United States
  • ACRC/Arizona Clinical Research Center, Incorporated
    Tucson, Arizona 85715, United States
  • Clinical Research Advantage, Inc./ Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Genova Clinical Research
    Tucson, Arizona 85741, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Fayetteville Diagnostic Clinic Limited
    Fayetteville, Arkansas 72703, United States
  • Hearne Family Practice Clinic
    Little Rock, Arkansas 72205, United States
  • Larry S. Watkins, M.D.
    Little Rock, Arkansas 72205, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72205, United States
  • Rx Medical Research of AR
    Little Rock, Arkansas 72205, United States
  • Anaheim Family Medical Center
    Anaheim, California 92804, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Advanced Arthritis & Rheumatology Center
    Artesia, California 90701, United States
  • Bina Akamdar MD
    Azusa, California 91702, United States
  • Rx for Life, Inc
    Bell, California 90201, United States
  • Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad
    Carlsbad, California 92008, United States
  • Capitol Interventional Cardiology
    Carmichael, California 95608, United States
  • Northern California Research
    Carmichael, California 95608, United States
  • CORE Orthopaedic Medical Center
    Encinitas, California 92024, United States
  • Arthritis Medical Clinic of North County, Inc.
    Escondido, California 92025, United States
  • Med Investigations, Inc.
    Fair Oaks, California 95628, United States
  • Valley Research
    Fresno, California 93720, United States
  • Creekside Clinical Research
    Greenbrae, California 94904, United States
  • C. V. Mehta, MD Medical Corporation
    Hemet, California 92543, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Alia Clinical Research, Inc
    Huntington Park, California 90255, United States
  • Time Clinical Research Inc.
    Huntington Park, California 90255, United States
  • Lindora Research Center
    Irvine, California 92604, United States
  • Office of Dr. Robert L. Freed, MD
    Irvine, California 92618, United States
  • Office of Dr. Alan Schenk
    Laguna Hills, California 92653, United States
  • Prime Care Clinical Research
    Laguna Hills, California 92653, United States
  • Jeremy Anuntiyo
    Lakewood, California 90712, United States
  • Premiere Clinical Research, LLC
    Lakewood, California 90712, United States
  • Stuart J. Finkelstein
    Lakewood, California 90712, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • VA Loma Linda Healthcare System
    Loma Linda, California 92357, United States
  • Narbonne Multi-Specialty Medical Group Inc.
    Lomita, California 90717, United States
  • Office of Dr. Arvind J. Mehta
    Long Beach, California 90806, United States
  • Pacific Internal Medicine Group, Inc
    Long Beach, California 90806, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807-0000, United States
  • National Institute of Clinical Research
    Long Beach, California 90807, United States
  • Alliance Research, LLC
    Long Beach, California 90813, United States
  • Valerius Medical Group and Research Center
    Los Alamitos, California 90720, United States
  • IMD Medical Group
    Los Angeles, California 90029, United States
  • Pacific Arthritis Care Center
    Los Angeles, California 90045, United States
  • Wagdy W. Kades, MD, Inc.
    Los Angeles, California 90057, United States
  • Samaritan Center for Medical Research Medical Group
    Los Gatos, California 95032, United States
  • Office of Lewis Gamarra, MD M.P.H.
    Los Osos, California 93402, United States
  • Adegbenga A. Adetola, M.D.
    Lynwood, California 90262, United States
  • Facey Medical Group
    Mission Hills, California 91345, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Desert Medical Group
    Palm Springs, California 92262, United States

Showing the first 100 of 1,066 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, Wolski KE, Xia F, Bao W, Walker C, Ruschitzka F, Nissen SE, Luscher TF. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 3;8(6):611-621. doi: 10.1093/ehjcvp/pvac015. PubMed 35234840 ↗
  • Chirikov VV, Walker C, Stephens JM, Schepman P, Chambers R, Bakir M, Poorman GW, Haider S, Farghaly M. Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial. Clinicoecon Outcomes Res. 2021 May 19;13:409-420. doi: 10.2147/CEOR.S280556. eCollection 2021. PubMed 34040400 ↗
  • Bao W, Gaffney M, Pressler ML, Fayyad R, Wisemandle W, Beckerman B, Wolski KE, Nissen SE. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION. Clin Trials. 2020 Oct;17(5):535-544. doi: 10.1177/1740774520934747. Epub 2020 Jul 9. PubMed 32643966 ↗
  • Solomon DH, Shao M, Wolski K, Nissen S, Husni ME, Paynter N. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis Rheumatol. 2019 Aug;71(8):1225-1231. doi: 10.1002/art.40870. Epub 2019 Jun 12. PubMed 30801994 ↗
  • Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeomans N, Luscher TF, Borer JS, Graham DY, Husni ME, Solomon DH, Libby P, Menon V, Lincoff AM, Nissen SE. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. J Am Coll Cardiol. 2018 Apr 24;71(16):1741-1751. doi: 10.1016/j.jacc.2018.02.036. PubMed 29673465 ↗
  • Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, Libby P, Lincoff AM, Luscher TF, Menon V, Yeomans ND, Wang Q, Bao W, Berger MF, Nissen SE; PRECISION Trial Investigators. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 Apr;70(4):537-546. doi: 10.1002/art.40400. PubMed 29266879 ↗
  • Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Luscher TF, Solomon DH, Husni ME, Graham DY, Davey DA, Wisniewski LM, Menon V, Fayyad R, Beckerman B, Iorga D, Lincoff AM, Nissen SE. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017 Nov 21;38(44):3282-3292. doi: 10.1093/eurheartj/ehx508. PubMed 29020251 ↗
  • Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13. PubMed 27959716 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2006 to primary completion in Apr 2016, 114 months.

Results were first posted in May 2017, 1 year after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 114 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2006
First posted
Jun 29, 2006
StartActual
Oct 4, 2006
Primary completionActual
Apr 12, 2016
CompletionActual
Apr 12, 2016
Results first posted
May 1, 2017
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00346216
Responsible party
Sponsor
First posted
Jun 29, 2006
Start date
Oct 4, 2006
Primary completion
Apr 12, 2016
Completion
Apr 12, 2016
Results posted
May 1, 2017
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion